Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Coronary Artery Anomalies Revisited: Description of the Types, Pathophysiology and Treatment Options Based on Latest Guidelines.

Journal of clinical medicine·2026
Same author

Tumor-naïve ctDNA detection with deep learning-enhanced error suppression for sensitive mutation calling.

Genome medicine·2026
Same author

Longitudinal Trends and Outcomes in Transcatheter Aortic Valve Implantation: a report from the SwissTAVI Registry.

Cardiovascular intervention and therapeutics·2026
Same author

mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1 are immunogenic, well tolerated and efficacious in rodent models.

Nature immunology·2026
Same author

Late Mitral Valve Stenosis After Transcatheter Edge-to-Edge Repair Due to Mixed Connective Tissue Disease.

The Canadian journal of cardiology·2026
Same author

Publisher Correction: Reproducibility and robustness of economics and political science research.

Nature·2026

Related Experiment Video

Updated: May 25, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Exploiting the mutanome for tumor vaccination.

John C Castle1, Sebastian Kreiter, Jan Diekmann

  • 1TRON-Translational Oncology at the University Medical Center Mainz, Germany.

Cancer Research
|January 13, 2012
PubMed
Summary

Cancer immunotherapy can be improved by targeting multiple mutations. This study identified immunogenic mutations in melanoma cells, demonstrating that mutated epitopes can effectively control tumor growth in mice, paving the way for personalized cancer vaccines.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
09:28

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

Related Experiment Videos

Last Updated: May 25, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
09:28

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Carcinogenesis involves multiple genetic events and clonal evolution, complicating single-target drug efficacy.
  • Tumor clonal heterogeneity presents an opportunity for multiepitope cancer vaccination strategies.

Purpose of the Study:

  • To comprehensively analyze the mutanome of B16F10 murine melanoma cells.
  • To assess the immunogenicity and specificity of identified nonsynonymous somatic point mutations.
  • To evaluate the potential of mutated epitopes as cancer vaccines in vivo.

Main Methods:

  • Next-generation sequencing (exome resequencing) to identify somatic mutations in B16F10 melanoma cells.
  • Validation of mutations and assessment of immunogenicity using long peptides encoding mutated epitopes in mice.
  • Evaluation of peptide immunization efficacy in tumor transplant models for protective and therapeutic effects.

Main Results:

  • Identified 962 nonsynonymous somatic point mutations, with 563 in expressed genes, including potential driver mutations.
  • One-third of validated mutated epitopes were immunogenic, with 60% showing preferential immune response against mutated sequences.
  • Peptide immunization demonstrated significant in vivo tumor control in both protective and therapeutic settings.

Conclusions:

  • Nonsynonymous base substitution mutations can serve as effective vaccine targets, even those with single amino acid substitutions.
  • The study provides a detailed mutanome profile of B16F10 melanoma, valuable for immunotherapy research.
  • Deep sequencing analysis of immunogenic mutations offers a promising approach for developing individualized cancer immunotherapies.